ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Review |
Article Title |
Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
|
Manuscript Source |
Invited Manuscript |
All Author List |
Elia Moreno-Cubero, Robert Sánchez-del-Arco, Julia Peña-Asensio, Eduardo Sanz-de-Villalobos, Joaquín Miquel and Juan Ramón Larrubia |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Gilead Spain & Instituto de Salud Carlos III |
GLD14_00217 |
Gilead Spain & Instituto de Salud Carlos III |
GLD16_00014 |
Instituto de Salud Carlos III, Spain & European Regional Development Fund (ERDF), a way of making Europe |
PI12/00130 |
Instituto de Salud Carlos III, Spain & European Regional Development Fund (ERDF), a way of making Europe |
PI15/00074 |
|
Corresponding Author |
Juan Ramón Larrubia, MD, MSc, PhD, Senior Lecturer, Staff Physician, Translational Hepatology Unit, Guadalajara University Hospital, University of Alcalá, Donante de Sangre st, Guadalajara E-19002, Spain. juan.larrubia@uah.es |
Key Words |
CD8; Lamivudine; Nucleos(t)ide analogues; Tenofovir; Chronic hepatitis B; Entecavir; hepatitis B virus; Treatment cessation |
Core Tip |
Nucleos(t)ide analogue (NA) treatment efficiently suppress hepatitis B virus replication. However, hepatitis B surface antigen loss, the optimal endpoint of NA therapy, is rarely achieved. Thus, a major unmet need in the management of chronic hepatitis B is the definition of earlier and safe treatment stopping points. There is growing clinical evidence that the majority of patients can benefit from this strategy after long-term NA therapy; yet, no criteria that distinguish which cases can safely stop treatment is established. We review here different biomarkers that could serve as a prognostic tool to safely discontinue therapy, focusing on host antiviral immunity. |
Publish Date |
2018-05-06 13:12 |
Citation |
Moreno-Cubero E, Sánchez del Arco RT, Peña-Asensio J, Sanz de Villalobos E, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 |
URL |
http://www.wjgnet.com/1007-9327/full/v24/i17/1825.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v24.i17.1825 |